Central Analgesic Drugs for the Treatment of Chronic Pain

Overview

Chronic pain is defined as pain that persists after healing of the wound that caused it, and can occur even in the absence of any obvious pathological trigger. In our country, there is a growing interest in the proper management of the disease "pain".

Pain is also the first symptom of the disease in 20 -50% of patients with neoplastic disease and from 75% to 90% of patients with advanced cancer suffers from chronic pain .

However, pain management is mostly inadequate. This study aims to assess the Italian clinical practice in reference to the pharmacological management of chronic pain by health professionals involved in the treatment of pain in some centers belonging to the Italian network of pain therapy.

Full Title of Study: “Cognitive Study on the Use of Central Analgesic Drugs in the Management of Chronic Pain”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: February 2016

Detailed Description

Chronic pain is defined as pain that persists after healing of the wound that caused it, and can occur even in the absence of any obvious pathological trigger. In our country, there is a growing interest in the proper management of the disease "pain".

In fact, the Ministry of Health, first in Europe, introduced a law in 2010 (March 15, 2010, No. 38) to provide for the sick, cancer or not, easy access to the necessary care and to provide specialists a specific training course.

Pain is also the first symptom of the disease in 20 -50% of patients with neoplastic disease and from 75% to 90% of patients with advanced cancer suffers from chronic pain (Marcus 2011).

The "pain disease" is one of the most common causes of access to medical care so it should be recognized as a complex health and research problem, being one of the most expensive and investigated conditions in our society (Pizzo and Clark, 2012; Gupta et al. , 2010; Dagenais et al., 2008).

It has a significant impact on the subjective perception of health status, influence daily activities and is associated with symptoms of depression and other psychological problems that affect the quality of life of the patient (end of 2011 Gureje et al., 1998; Bair et al., 2003, Portenoy, 1996).

However, pain management is mostly inadequate for several medical and social reasons: difficulty in defining the complexity of its pathophysiology, difficulty in finding animal models useful for the development of analgesic drugs, difficulty in finding clinical models predictive of drug efficacy / security, lack of recognition of pain as a health issue and not adequate academic training.

A recent survey in Europe uncovered alarming data: 40% of surveyed patients (46,394) reported an inadequate treatment of accused pain (Breivik et al., 2006).

There are also several open questions regarding the research on the most powerful analgesic drugs used: opioids (Galer et al 1992).

There is no specific experimental model able to solve the three most pressing problems: the predictability of the patient's response, efficacy and safety of opioids.

There is no scientific evidence for the efficacy / safety of long-term use of opioids in chronic pain (Chapman et al., 2010; Manchikanti et al., 2011).

A recent review showed that approximately 22% of patients, suffering from chronic pain and on opioid therapy, suspends therapy for the occurrence of side effects and 5-10% of patients suspend it for a not proper control of pain symptoms (Noble et al., 2010).

This study aims to assess the Italian clinical practice in reference to the pharmacological management of chronic pain by health professionals involved in the treatment of pain in some centers belonging to the Italian network of pain therapy.

Clinical Trial Outcome Measures

Primary Measures

  • adherence to therapy
    • Time Frame: 18 months
    • to evaluate the proportion of patients who continues therapy with benefit after one month of enrollment

Secondary Measures

  • adherence at 6 months
    • Time Frame: 18 months
    • differences between the central analgesic drugs in the percentage of patients who continue therapy (adherence) at 1 month and 6 months
  • side effects
    • Time Frame: 18 months
    • difference between the central analgesic drugs in the percentage of patients who develop side effects
  • quality of life
    • Time Frame: 18 months
    • difference between the central analgesic drugs with regard to the improvement of quality of life reported by the patient

Participating in This Clinical Trial

Inclusion Criteria

  • Males and females over the age of 18 years
  • Chronic neuropathic and / or nociceptive and / or mixed pain, whereby clinicians considers necessary to start opioid therapy
  • Signed informed consent

Exclusion Criteria

  • Males and females aged under 18 years
  • Patients already receiving opioid analgesic drugs or drugs of the class MOR-NRI.
  • Taking abuse drugs or alcohol abuse
  • Patients with contraindications to the use of central analgesic drugs
  • Patients who refuse participation
  • Prior cognitive impairment or mental retardation
  • Severe immunodeficiency (WBC <4,000)
  • Severe renal impairment (serum creatinine > 2g/dl or Creatinine clearance <30 ml / h)
  • Hepatic impairment (Cholinesterase <2.000UI or INR> 2)

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Parma
  • Provider of Information About this Clinical Study
    • Principal Investigator: Christian Compagnone, MD – University of Parma
  • Overall Official(s)
    • Christian Compagnone, Principal Investigator, University of Parma
  • Overall Contact(s)
    • Christian Compagnone, 0521-703567, ccompagnone@parmanesthesia.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.